Judo Bio, a Cambridge, MA-based biotechnology company developing oligonucleotide medicines delivered to the kidney, raised $100M in Seed and Series A financing
Atlas Venture founded and incubated Judo Bio with The Column Group joining the seed financing. The Series A was recently closed and co-led by Atlas Venture, TCG and Droia Ventures, with participation from Digitalis Ventures, Euclidean Capital, Alexandria Venture Investments, YK Bioventures, and other undisclosed funds.
The company intends to use the funds to advance the lead ligand-siRNA conjugate to the clinic and to further build its proprietary STRIKE (Selectively Targeting RNA Into KidnEy) platform.
Judo Bio is developing oligonucleotide medicines delivered to the kidney, opening the way for new genetic medicines for systemic and renal diseases. With its STRIKE (Selectively Targeting RNA Into KidnEy) platform, the company is using a proprietary approach to create ligand-RNA conjugate drugs designed for receptor-mediated update by specific kidney cell types, resulting in gene silencing of disease-modifying target genes.
Its initial pipeline programs are megalin-STRIKERs that use the megalin receptor family to selectively deliver siRNA therapeutics to the proximal tubule of the kidney to silence mRNA expression of specific solute carrier proteins (SLCs), thereby inhibiting the uptake of circulating solutes linked to systemic diseases.
Judo Bio also announced the appointment of biopharma industry veteran Rajiv Patni, M.D., as the companyās Chief Executive Officer and Board director.
FinSMEs
07/10/2024